Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyHealth New England CAR-T Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentHealth-New-EnglandPolicy UM699POL

    Chimeric Antigen Receptor T-Cell Therapy - Medical Policy

    Customize your policy alerts

    Sign up for Health-New-England Policy UM699POL alerts

    Get alerted when Policy UM699POL changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and site-of-service review for CAR-T therapy for Health New England Commercial, Medicare Advantage, and Medicaid (BeHealthy) members. Drug approval must be obtained through the applicable pharmacy or Medicaid utilization-review process before site-of-service review.

    Policy Summary
    PayerHealth-New-England
    PolicyChimeric Antigen Receptor T-Cell Therapy
    Policy CodePolicy UM699POL
    Change TypeRevised
    Effective DateJune 1, 2026
    Next Review DateN/A
    Key ActionSubmit Commercial and Medicare CAR-T therapy requests and listed procedure codes to Prime Therapeutics for approval before Health New England reviews site of service.
    SourceLink
    POLICY UPDATE CHANGES

    Universal criteria were removed from the policy in January 2026.

    CAR-T procedure coding was updated from prior codes to CPT 38225 through 38228 in November 2024.

    The Commercial and Medicare drug-approval process is routed through Prime Therapeutics, while Medicaid approval is routed through the MassHealth Drug Utilization Review Program.

    3Lines of business included
    4CAR-T procedure CPT codes listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    PA required
    Authorization status for listed CPT codes
    4 stagesCAR-T treatment process described

    CAR-T Procedure Coding

    CAR-T procedure codesCPT
    38225Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per
    38226Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day
    38227Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells for administration
    38228Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous
    Code added in policy implementation historyHCPCS
    C9301Code added to the coding table; description not provided in the supplied policy text

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain Prime Therapeutics approval

    Commercial and Medicare requests for CAR-T therapy must be submitted to Prime Therapeutics. Prime Therapeutics approval of the CAR-T drug is required before Health New England reviews the site of service.

    • This requirement applies to CPT codes 38225, 38226, 38227, and 38228.
    • Each listed CPT code requires prior authorization.
    Prior Authorization

    Obtain MassHealth DUR approval

    Medicaid (BeHealthy) CAR-T therapy requests must be submitted to the MassHealth Drug Utilization Review (DUR) Program. MassHealth approval is obtained through the MassHealth DUR process before the applicable review.

    • This requirement applies to CPT codes 38225, 38226, 38227, and 38228.
    • Each listed CPT code requires prior authorization.
    Documentation Required

    Submit clinical evidence

    The treating physician or primary care provider must submit clinical evidence and documentation showing that the patient meets the applicable treatment criteria. Without this information, Health New England will not be able to properly review the prior authorization request.

    CAR-T Therapy Overview

    Chimeric antigen receptor T-cell (CAR-T) therapy is an adoptive immunotherapy, also called adoptive T-cell therapy, that uses a patient's own immune cells to recognize and attack cancer cells. The treatment occurs in four stages: the patient's T cells are collected through leukapheresis; the cells are genetically modified in a laboratory to express chimeric antigen receptors; the modified cells are expanded and prepared for treatment; and the cells are infused back into the patient to target tumor cells carrying the corresponding antigen.

    Key Terms

    Chimeric Antigen Receptor (CAR) T-Cell Therapy
    TypeImmunotherapy
    Also calledAdoptive T-cell therapy
    PurposeAttempts to program the patient’s own immune system to recognize and attack cancer cells
    Leukapheresis
    Procedure typeLaboratory procedure
    Cells separatedWhite blood cells (WBCs)
    SourceA blood sample
    Policy Summary
    PayerHealth-New-England
    PolicyChimeric Antigen Receptor T-Cell Therapy
    Policy CodePolicy UM699POL
    Change TypeRevised
    Effective DateJune 1, 2026
    Next Review DateN/A
    Key ActionSubmit Commercial and Medicare CAR-T therapy requests and listed procedure codes to Prime Therapeutics for approval before Health New England reviews site of service.
    SourceLink
    On This Page
    CAR-T Procedure CodingAuthorization and Documentation RequirementsCAR-T Therapy OverviewKey Terms
    Apheresis
    ProcessSeparating out one particular constituent of blood
    Blood componentOne particular constituent of blood
    Remaining bloodReturned to the circulation
    Autologous Stem Cell Transplantation
    ProcessBlood-forming stem cells are removed and stored
    Subsequent stepThe stored stem cells are later given back
    RecipientThe same person from whom the cells were removed
    Allogenic Stem Cell Transplantation
    ProcessA person receives blood-forming stem cells
    Donor relationshipA genetically similar but not identical donor
    Possible donorsA sister, brother, or unrelated donor
    Relapsed or Refractory Disease
    Disease progressionProgression after two or more lines of systemic therapy
    Treatment responseFailure to achieve a partial remission or complete remission to the last regimen
    Autologous transplant therapyMay or may not be included